Sugammadex Reduced the Incidence of Postoperative Pulmonary Complications in Susceptible Patients Identified by ARISCAT Risk Index: Systematic Review and Meta-analysis

Overview

Journal Adv Ther

Date 2023 Jun 23

PMID 37351811

Authors

Yun-Xiao Bai

Jing-Jing Han

Jie Liu

Xia Li

Zhen-Zhen Xu

Yong Lv

Ke-Xuan Liu

Qing-Ping Wu

Affiliations

Soon will be listed here.

Abstract

Introduction: The efficacy of sugammadex on postoperative pulmonary complications (PPCs) in susceptible patients, compared with neostigmine, remains indeterminate. The Assess Respiratory Risk in Surgical Patients in Catalonia (ARISCAT) Group Investigators proposed a risk index for the early identification of susceptible patients, with excellent externally validated discrimination ability. Meta-analytical techniques were applied to evaluate the efficacy of sugammadex on PPCs in patients with ARISCAT-defined risk factors.

Methods: The study is registered on PROSPERO, number CRD42021261156. We searched PubMed, Scopus, Embase, Cochrane library, GreyNet, and OpenGrey for eligible randomized controlled trials (RCTs) without restricting the language or year of publication.

Results: Twelve RCTs consisting of 1182 patients susceptible to PPCs were included. A robust reduction was observed on the incidence of PPCs in susceptible patients who received sugammadex [RR 0.66; 95% CI (0.54, 0.80), p < 0.01], with a low level of between-study heterogeneity (I = 45.98%; H = 1.85). Similar protective effects were also proved in avoiding residual neuromuscular block (NMB) [RR 0.25; 95% CI (0.11, 0.56); p < 0.01], atelectasis [RR 0.74; 95% CI (0.59, 0.95); p = 0.02], pneumonia [RR 0.49; 95% CI (0.28, 0.88); p = 0.02], and respiratory failure [RR 0.61; 95% CI (0.39, 0.96); p = 0.03]. No difference was observed regarding adverse events [RR 0.85; 95% CI (0.72, 1.01); p = 0.06].

Conclusion: Low to moderate quality of evidence demonstrated the edge of sugammadex over neostigmine for NMB reversal in reducing the likelihood of PPCs and residual NMB in patients with ARISCAT-defined risk factors. Clinicians may reassess the type of reversal agent when treating patients susceptible to PPCs.

References

Miskovic A, Lumb A . Postoperative pulmonary complications. Br J Anaesth. 2017; 118(3):317-334. DOI: 10.1093/bja/aex002. View

McAlister F, Bertsch K, Man J, Bradley J, Jacka M . Incidence of and risk factors for pulmonary complications after nonthoracic surgery. Am J Respir Crit Care Med. 2004; 171(5):514-7. DOI: 10.1164/rccm.200408-1069OC. View

Canet J, Gallart L, Gomar C, Paluzie G, Valles J, Castillo J . Prediction of postoperative pulmonary complications in a population-based surgical cohort. Anesthesiology. 2010; 113(6):1338-50. DOI: 10.1097/ALN.0b013e3181fc6e0a. View

Rahe-Meyer N, Berger C, Wittmann M, Solomon C, Abels E, Rietbergen H . Recovery from prolonged deep rocuronium-induced neuromuscular blockade: A randomized comparison of sugammadex reversal with spontaneous recovery. Anaesthesist. 2015; 64(7):506-12. DOI: 10.1007/s00101-015-0048-0. View

Jones R, Caldwell J, Brull S, Soto R . Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine. Anesthesiology. 2008; 109(5):816-24. DOI: 10.1097/ALN.0b013e31818a3fee. View

Lawrence V, Hilsenbeck S, Mulrow C, Dhanda R, Sapp J, Page C . Incidence and hospital stay for cardiac and pulmonary complications after abdominal surgery. J Gen Intern Med. 1995; 10(12):671-8. DOI: 10.1007/BF02602761. View

Canet J, Sabate S, Mazo V, Gallart L, de Abreu M, Belda J . Development and validation of a score to predict postoperative respiratory failure in a multicentre European cohort: A prospective, observational study. Eur J Anaesthesiol. 2015; 32(7):458-70. DOI: 10.1097/EJA.0000000000000223. View

Mazo V, Sabate S, Canet J, Gallart L, de Abreu M, Belda J . Prospective external validation of a predictive score for postoperative pulmonary complications. Anesthesiology. 2014; 121(2):219-31. DOI: 10.1097/ALN.0000000000000334. View

Jin Y, Xie G, Wang H, Jin L, Li J, Cheng B . Incidence and risk factors of postoperative pulmonary complications in noncardiac Chinese patients: a multicenter observational study in university hospitals. Biomed Res Int. 2015; 2015:265165. PMC: 4363533. DOI: 10.1155/2015/265165. View

10.

Kokotovic D, Degett T, Ekeloef S, Burcharth J . The ARISCAT score is a promising model to predict postoperative pulmonary complications after major emergency abdominal surgery: an external validation in a Danish cohort. Eur J Trauma Emerg Surg. 2022; 48(5):3863-3867. DOI: 10.1007/s00068-021-01826-6. View

11.

Murphy G, Szokol J, Marymont J, Greenberg S, Avram M, Vender J . Intraoperative acceleromyographic monitoring reduces the risk of residual neuromuscular blockade and adverse respiratory events in the postanesthesia care unit. Anesthesiology. 2008; 109(3):389-98. DOI: 10.1097/ALN.0b013e318182af3b. View

12.

Hristovska A, Duch P, Allingstrup M, Afshari A . The comparative efficacy and safety of sugammadex and neostigmine in reversing neuromuscular blockade in adults. A Cochrane systematic review with meta-analysis and trial sequential analysis. Anaesthesia. 2017; 73(5):631-641. DOI: 10.1111/anae.14160. View

13.

Krause M, McWilliams S, Bullard K, Mayes L, Jameson L, Mikulich-Gilbertson S . Neostigmine Versus Sugammadex for Reversal of Neuromuscular Blockade and Effects on Reintubation for Respiratory Failure or Newly Initiated Noninvasive Ventilation: An Interrupted Time Series Design. Anesth Analg. 2019; 131(1):141-151. PMC: 7379749. DOI: 10.1213/ANE.0000000000004505. View

14.

Colquhoun D, Vaughn M, Bash L, Janda A, Shah N, Ghaferi A . Association between choice of reversal agent for neuromuscular block and postoperative pulmonary complications in patients at increased risk undergoing non-emergency surgery: STIL-STRONGER, a multicentre matched cohort study. Br J Anaesth. 2022; 130(1):e148-e159. PMC: 9875908. DOI: 10.1016/j.bja.2022.04.023. View

15.

Wang J, Zhao Z, Jiang Z, Liu H, Deng X . Influence of sugammadex versus neostigmine for neuromuscular block reversal on the incidence of postoperative pulmonary complications: a meta-analysis of randomized controlled trials. Perioper Med (Lond). 2021; 10(1):32. PMC: 8451127. DOI: 10.1186/s13741-021-00203-6. View

16.

Yagan O, Tas N, Mutlu T, Hanci V . Comparison of the effects of sugammadex and neostigmine on postoperative nausea and vomiting. Braz J Anesthesiol. 2017; 67(2):147-152. DOI: 10.1016/j.bjane.2015.08.003. View

17.

Hakimoglu S, Tuzcu K, Davarci I, Karcioglu M, Tuzcu E, Hanci V . Comparison of sugammadex and neostigmine-atropine on intraocular pressure and postoperative effects. Kaohsiung J Med Sci. 2016; 32(2):80-5. DOI: 10.1016/j.kjms.2016.01.009. View

18.

Geldner G, Niskanen M, Laurila P, Mizikov V, Hubler M, Beck G . A randomised controlled trial comparing sugammadex and neostigmine at different depths of neuromuscular blockade in patients undergoing laparoscopic surgery. Anaesthesia. 2012; 67(9):991-8. DOI: 10.1111/j.1365-2044.2012.07197.x. View

19.

Ba Y, Liu Y, He S, Li H, Wang H, Zhu J . [Analysis of sugammadex for antagonistic neuromuscular block in patients with radical resection of lung cancer under thoracoscope]. Zhonghua Yi Xue Za Zhi. 2020; 100(3):213-219. DOI: 10.3760/cma.j.issn.0376-2491.2020.03.011. View

20.

Liberati A, Altman D, Tetzlaff J, Mulrow C, Gotzsche P, Ioannidis J . The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009; 6(7):e1000100. PMC: 2707010. DOI: 10.1371/journal.pmed.1000100. View